Arthritis Care & Research· 2012Q1· Review
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- 1,803citations
- Q1SCImago
- 2012year
Short summary
Updated guidelines provide recommendations for using conventional synthetic, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA) treatment.
AI-generated from the title and abstract; the full text is not read.
Key points
- Provides updated recommendations for RA treatment using DMARDs.
- Covers conventional synthetic, targeted synthetic, and biologic agents.
- Aims to guide clinical decision-making for rheumatoid arthritis management.
AI-generated from the title and abstract; the full text is not read.
Abstract
Peer Reviewed
The authors' abstract, as published at the source. Arthritis Care & Research, 2012 · DOI ↗
TakeawaysPremium
Ask the paperFree account
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Rheumatology
RheumatologyMedicine